Neonatal BCG vaccination and child survival in TB-exposed and TB-unexposed children: a prospective cohort study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
28 02 2020
Historique:
entrez: 2 3 2020
pubmed: 3 3 2020
medline: 16 2 2021
Statut: epublish

Résumé

To assess the association between neonatal BCG vaccination and mortality between 28 days and 3 years of age among tuberculosis (TB)-exposed and TB-unexposed children. Prospective cohort study. Bandim Health Project runs an urban Health and Demographic Surveillance site in Guinea-Bissau with registration of mortality, vaccination status and TB cases. Children entered the analysis when their vaccination card was inspected after 28 days of age and remained under surveillance to 3 years of age. Children residing in the same house as a TB case were classified as TB-exposed from 3 months prior to case registration to the end of follow-up. Using Cox-proportional hazards models with age as underlying time scale, we compared mortality of children with and without neonatal BCG between October 2003 and September 2017. HR for neonatal BCG compared with no neonatal BCG by TB-exposure status. Among the 39 421 children who entered the analyses, 3022 (8%) had observation time as TB-exposed. In total, 84% of children received neonatal BCG. Children with neonatal BCG had lower mortality both in TB-exposed (adjusted HR: 0.57 (0.26 to 1.27)) and in TB-unexposed children (HR: 0.57 (95% CI 0.47 to 0.69)) than children without neonatal BCG. Children exposed to TB had higher mortality than TB-unexposed children if they had not received neonatal BCG. Neonatal BCG vaccination was associated with lower mortality among both TB-exposed and TB-unexposed children, consistent with neonatal BCG vaccination having beneficial non-specific effects. Interventions to increase timely BCG vaccination are urgently warranted.

Identifiants

pubmed: 32114478
pii: bmjopen-2019-035595
doi: 10.1136/bmjopen-2019-035595
pmc: PMC7050365
doi:

Substances chimiques

BCG Vaccine 0

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e035595

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

BMJ. 2016 Oct 13;355:i5170
pubmed: 27737834
Pneumonia (Nathan). 2016;8:
pubmed: 28003956
Pediatr Infect Dis J. 2019 Feb;38(2):195-197
pubmed: 30640189
Paediatr Respir Rev. 2004;5 Suppl A:S135-7
pubmed: 14980258
BMJ. 2010 Nov 30;341:c6495
pubmed: 21118875
Lancet. 2009 May 2;373(9674):1543-9
pubmed: 19303633
Trop Med Int Health. 2014 Nov;19(11):1367-76
pubmed: 25145557
Int J Tuberc Lung Dis. 2011 Dec;15(12):1637-43
pubmed: 22118171
Lancet Glob Health. 2018 Dec;6(12):e1329-e1338
pubmed: 30266570
Clin Infect Dis. 2014 Feb;58(4):470-80
pubmed: 24336911
Clin Infect Dis. 2000 Sep;31 Suppl 3:S71-4
pubmed: 11010826
Clin Infect Dis. 2017 Oct 1;65(7):1183-1190
pubmed: 29579158
Vaccine. 2018 Jun 7;36(24):3406-3407
pubmed: 29748032
MMWR Morb Mortal Wkly Rep. 2018 Nov 16;67(45):1261-1264
pubmed: 30439873
Chest. 1991 Feb;99(2):416-9
pubmed: 1989804
PLoS Med. 2011 Oct;8(10):e1001105
pubmed: 22022234
Lancet Glob Health. 2018 Dec;6(12):e1260-e1261
pubmed: 30266569
Int J Epidemiol. 2004 Apr;33(2):374-80
pubmed: 15082643
BMJ. 2010 Mar 15;340:c671
pubmed: 20231251
Cell Host Microbe. 2018 Jan 10;23(1):89-100.e5
pubmed: 29324233
Clin Infect Dis. 2015 Nov 15;61(10):1504-11
pubmed: 26219694
Front Immunol. 2018 Dec 04;9:2869
pubmed: 30564249
Wkly Epidemiol Rec. 2018 Feb 23;93(8):73-96
pubmed: 29474026
Thorax. 2002 Sep;57(9):804-9
pubmed: 12200526
BMJ Open. 2013 Mar 26;3(3):
pubmed: 23535699
Thorax. 2011 Feb;66(2):163-7
pubmed: 21148136
Pediatr Infect Dis J. 2019 Feb;38(2):198-202
pubmed: 30256314
Health Technol Assess. 2013 Sep;17(37):1-372, v-vi
pubmed: 24021245
Pediatr Infect Dis J. 2004 Jun;23(6):544-50
pubmed: 15194836
BMJ. 2000 Dec 9;321(7274):1435-8
pubmed: 11110734
Eur Respir J. 2013 Jan;41(1):140-56
pubmed: 22936710

Auteurs

Sanne M Thysen (SM)

Bandim Health Project, OPEN, University of Southern Denmark, Odense, Syddanmark, Denmark s.thysen@bandim.org.
Bandim Health Project, Bissau, Guinea-Bissau.
Research Center for Vitamins and Vaccines, Bandim Health Project, Statens Serum Institut, Copenhagen, Denmark.
Center for Global Health (GloHAU), Department of Public Health, Aarhus University, Aarhus, Denmark.

Christine Stabell Benn (CS)

Bandim Health Project, OPEN, University of Southern Denmark, Odense, Syddanmark, Denmark.
Bandim Health Project, Bissau, Guinea-Bissau.
Research Center for Vitamins and Vaccines, Bandim Health Project, Statens Serum Institut, Copenhagen, Denmark.

Victor Francisco Gomes (VF)

Bandim Health Project, Bissau, Guinea-Bissau.

Frauke Rudolf (F)

Bandim Health Project, Bissau, Guinea-Bissau.
Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.

Christian Wejse (C)

Bandim Health Project, Bissau, Guinea-Bissau.
Center for Global Health (GloHAU), Department of Public Health, Aarhus University, Aarhus, Denmark.
Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.

Adam Roth (A)

Department of Communicable Disease Control and Health Protection, Public Health Agency of Sweden, Solna, Stockholm, Sweden.
Department of Translational Medicine, Lund University, Lund, Sweden.

Per Kallestrup (P)

Center for Global Health (GloHAU), Department of Public Health, Aarhus University, Aarhus, Denmark.

Peter Aaby (P)

Bandim Health Project, Bissau, Guinea-Bissau.
Research Center for Vitamins and Vaccines, Bandim Health Project, Statens Serum Institut, Copenhagen, Denmark.

Ane Fisker (A)

Bandim Health Project, Bissau, Guinea-Bissau.
Research Center for Vitamins and Vaccines, Bandim Health Project, Statens Serum Institut, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH